Necrotizing vasculitis due to gefitinib (Iressa®) [5]

International Journal of Dermatology

Volumn 46, Issue 8, 2007, Pages 890-891

  Fernández Guarino, Montse ^a   Ryan, Ainhoa Marquet ^a   Pérez García, Bibiana ^a   Gónzalez López, Carmen ^a   Olasolo, Pedro Jaén ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB;

ADENOID CYSTIC CARCINOMA; ADULT; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; LETTER; LUNG NODULE; LUNG RESECTION; MALE; MAXILLA CANCER; MAXILLA RESECTION; NECROTIZING ARTERITIS; PURPURA; PUSTULE; SKIN BIOPSY; SKIN EXFOLIATION;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; SKIN; VASCULITIS;

EID: 34547406731     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03275.x     Document Type: Letter

References (6)

1. Kurokawa I, Endo K, Hirabayashi M. Purpuric drug eruption possibly due to gefitinib (Iressa®). Int J Dermatol 2005; 44: 167-168.
2. Lee M-W, Seo C-W, Kim S-W, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004; 84: 23-26.
3. Herbst RS, Lo Russo P, Purdum M, et al. Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clin Lung Cancer 2003; 4: 366-369.
4. Van Doorm R, Kirtsching G, Shoeffer E. Follicular an epidermal alterations in patients treated with ZD 1839 (Iressa) an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601.
5. Fernández-Guarino M, Aldanondo I, Gonzalez-García C, et al. Gefitinib-induced perforating dermatosis. Actas Dermosifiliogr 2006; 96: 208-211.
6. Nanney LB, Magid M, Stoschek CM, et al. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83: 385-393.